U.S. lawmakers on Friday announced an investigation into the approval and pricing of Biogen Inc’s Alzheimer’s drug, Aduhelm, amid concerns over its steep price and doubts if the clinical evidence proves the drug works.
US lawmakers to investigate approval, pricing of Alzheimer’s drug from Biogen
